C. Brander et al., CARRIER-MEDIATED UPTAKE AND PRESENTATION OF A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-RESTRICTED PEPTIDE, European Journal of Immunology, 23(12), 1993, pp. 3217-3223
Antigenic peptides derived from endogenous or viral proteins can assoc
iate with class I or class II major histocompatibility complex (MHC) m
olecules, while exogenous antigens are endocytosed, processed intracel
lularly and presented on MHC class II molecules. Here we describe a me
thod that allows the presentation of an MHC class I-restricted antigen
ic peptide on MHC class I molecules, although it was taken up from the
outside. The HLA-A2-restricted influenza virus matrix protein-derived
peptide (flu, 57-68) was used either in soluble form or coupled via a
n S-S bridge to transferrin (Tf-flu). Target cells were incubated with
flu or Tf-flu and the effective antigen presentation was detected in
a cytotoxicity assay using flu peptide-specific, HLA-A2-restricted CD8
+ cytotoxic T lymphocytes. Sensitization of target cells with Tf-flu r
equired 5 to 10 times higher molar concentrations of peptide compared
to sensitization with soluble free peptide. The Tf-flu construct was t
aken up by the cells via the Tf receptor (CD71) as the binding of Tf-f
lu was blocked by an excess of Tf. In contrast to the flu peptide, cyt
otoxicity elicited by Tf-flu was blocked by brefeldin A but not by chl
oroquine nor inhibitors of intracellular reducing steps, like 1-buthio
nine-(s,r)-sulfoximine or n-ethylmaleimide. Presentation of the flu pe
ptide derived from Tf-flu construct is not hindered in the mutant T2 c
ell line, which lacks genes coding for transporter proteins for antige
nic peptides (TAP1/TAP2) and proteasomes subunits, suggesting that the
processing pathway described in this report may involve TAP-independe
nt steps.